Vimarsana
Biggest News Aggregation in the World

Page 46 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Investegate |Hyundai Motor Co Announcements | Hyundai Motor Co: Guidance for 2021 - Vimarsana News

Investegate |Hyundai Motor Co Announcements | Hyundai Motor Co: Guidance for 2021

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...

Junshi Biosciences: New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent - Vimarsana News

Junshi Biosciences: New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent

Junshi Biosciences: New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent Results from more than 1,000 high-risk patients were consistent with previous data In November, Lilly submitted a EUA request to the FDA for etesevimab and bamlanivimab together for mild to moderate COVID-19 in high-risk patients, which remains under review by the FDA Findings from BLAZE-4 trial provide data on lower doses of etesevimab and bamlanivimab together SHANGHAI, China, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (H...

New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent | Comunicados | Edición USA - Vimarsana News

New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent | Comunicados | Edición USA

Trial met primary endpoint and key secondary endpoints with high statistical significance Results from more than 1,000 high-risk patients were consistent with previous data In November, Lilly submitted a EUA request to the FDA for etesevimab and bamlanivimab together for mild to moderate COVID-19 in high-risk patients, which remains under review by the FDA Findings from BLAZE-4 trial provide data on lower doses of etesevimab and bamlanivimab together SHANGHAI, China, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical...

Source: efe.com
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma - Vimarsana News

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

SHANGHAI, China, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated...

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon delivers Okhta House residential complex - Vimarsana News

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon delivers Okhta House residential complex

About Etalon Group Founded in 1987, Etalon Group is one of Russia's largest development and construction companies. The Company focuses on middle class residential real estate in the Moscow and St Petersburg metropolitan areas. With a more than 30-year history, Etalon Group has one of the longest and most successful track records in the Russian real estate industry. Since its foundation, Etalon Group has commissioned 7 million sqm of real estate. The Company is vertically integrated, which helps it to control costs, quality and timing, as well as maintain best-in-class profitability. Et...